CompletedInterventionalPhase 3Last updated Aug 7, 2009

Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV

Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant

Overview

ClinicalTrials.gov ID: NCT00074399
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)NIH
Brief Summary: HIV can be transmitted from an HIV infected mother to her infant through her breast milk. The purpose of this study is to determine whether giving infants of HIV infected mothers the anti-HIV drug nevirapine (NVP) for six weeks will reduce the risk of HIV transmission.

Study hypothesis: Six weeks of nevirapine prophylaxis provided to the infant will decrease HIV transmission through breastfeeding.

Status

Overall Status: Completed
Start Date: Feb 2001
Primary Completion Date: Apr 2007Actual
Completion Date: Apr 2007Actual

Study Record Dates

First Submitted: Dec 11, 2003
First Submitted that Met QC Criteria: Dec 12, 2003
First Posted: Dec 15, 2003Estimated
Last Update Submitted that Met QC Criteria: Aug 6, 2009
Last Update Posted: Aug 7, 2009Estimated
Last Verified: Aug 2009

NCT00074412Completed

Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

NCT00001135Completed

A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants

NCT00000942Completed

A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies

NCT00006279Completed

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

NCT00000869Completed

A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies

NCT00061321Completed

Daily Nevirapine to Prevent Mother to Infant Transmission of HIV